Kynamro
Generic name: mipomersen
Treatment for: High Cholesterol, Familial Homozygous
Isis Pharmaceuticals to Discuss Productive Regulatory Discussions Regarding the Mipomersen NDA Filing
CARLSBAD, Calif., Jan. 10, 2011 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today that it will hold a conference call focused on Genzyme's recent regulatory discussions with the FDA about the mipomersen NDA filing.
Genzyme plans to communicate at its JP Morgan presentation Tuesday that:
- It had a productive meeting with the FDA.
- Based on FDA feedback, it believes the mipomersen package for HoFH is sufficient for filing.
- Due to the size of the severe HeFH population, the FDA provided guidance for additional 12 month exposure data before the mipomersen filing for severe HeFH. The Genzyme team is working with the FDA to further define the study required. FDA acknowledged that an outcome study may not be feasible in severe HeFH patients due to the size of the population.
- The EU filing continues on track toward a 1H filing for HoFH and may include severe HeFH.
- As Genzyme incorporates the FDA feedback, it will determine the timing for the US HoFH filing, which may shift to the second half of the year.
About Isis Pharmaceuticals, Inc.
Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 24 drugs in development. Isis' drug development programs are focused on treating cardiovascular, metabolic, and severe neurodegenerative diseases and cancer. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Isis and Alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development and commercialization of microRNA therapeutics. Isis also has made significant innovations beyond human therapeutics resulting in products that other companies, including Abbott, are commercializing. As an innovator in RNA-based drug discovery and development, Isis has designed and executed a patent strategy that has provided the Company with strong and extensive protection for Isis' drugs as well as all aspects of antisense drug discovery, development and manufacturing.
Forward-Looking Statements
This press release includes forward-looking statements regarding Isis' collaboration with Genzyme Corporation, its financial and business development activities, and the development, activity, therapeutic potential and safety of mipomersen in treating patients with high cholesterol. Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2009 and its most recent quarterly report on Form 10-Q, which are on file with the SEC. Copies of these and other documents are available from the Company.
In this press release, unless the context requires otherwise, "Isis", "Company", "we", "our", and "us" refers to Isis Pharmaceuticals and its subsidiaries, including Regulus Therapeutics Inc.
Isis Pharmaceuticals is a registered trademark of Isis Pharmaceuticals, Inc. Regulus Therapeutics is a trademark of Regulus Therapeutics Inc.
SOURCE Isis Pharmaceuticals, Inc.
CONTACT: Kristina Lemonidis, Director, Corporate Communications, +1-760-603-2490, or Amy Blackley, Ph.D., Assistant Director, Corporate Communications, +1-760-603-2772, both of Isis Pharmaceuticals, Inc.
Posted: January 2011
Related articles
- FDA Approves New Orphan Drug Kynamro to Treat Inherited Cholesterol Disorder - January 30, 2013
- FDA Advisory Committee Recommends Kynamro for Homozygous Familial Hypercholesterolemia - October 19, 2012
- Genzyme and Isis Announce Filing of U.S. NDA for Kynamro (Mipomersen Sodium) in Homozygous Familial Hypercholesterolemia - May 29, 2012
- Genzyme and Isis Announce Submission of U.S. NDA for Kynamro (mipomersen sodium) in Homozygous Familial Hypercholesterolemia - March 29, 2012
Kynamro (mipomersen) FDA Approval History
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
